12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nexavar sorafenib: Phase III data

The double-blind, international Phase III SEARCH trial in 720 patients with unresectable HCC showed that twice-daily 400 mg oral Nexavar plus once-daily 150 mg oral Tarceva erlotinib missed the primary endpoint of OS vs. Nexavar plus placebo. Details were not disclosed. Nexavar is approved in more than 100 countries...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >